286.24MMarket Cap-3.63P/E (TTM)
3.440High3.280Low341.78KVolume3.420Open3.380Pre Close1.15MTurnover0.44%Turnover RatioLossP/E (Static)83.94MShares3.80052wk High4.38P/B262.28MFloat Cap1.39052wk Low--Dividend TTM76.92MShs Float396.060Historical High--Div YieldTTM4.73%Amplitude1.080Historical Low3.368Avg Price1Lot Size
aTyr Pharma Stock Forum
aTyr Pharma’s Lead Therapeutic Candidate Efzofitimod for Pulmonary Sarcoidosis to be Featured in Best of CHEST Journals at CHEST 2024 Annual Meeting
aTyr Pharma Announces Publication Demonstrating Efficacy of Efzofitimod in Pulmonary Sarcoidosis in the European Respiratory Journal
Post hoc analysis of Phase 1b/2a study demonstrated statistically significant difference in time-to-first-relapse for corticosteroid use in therapeutic (3.0 and 5.0 mg/kg efzofitimod) vs subtherapeutic (1.0 mg/kg efzofitimod and placebo) groups.
54.4% of patients in the subtherapeutic group relapsed following corticosteroid taper, compar...
No comment yet